Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill requires the President to appoint separate Inspectors General (IGs) for the National Institutes of Health, the Centers for Disease Control and Prevention, and the Food and Drug Administration within one year. It amends Title 5 definitions to include those agencies and specifies that implementation uses existing Office of Inspector General funds at HHS, with no new appropriations authorized.
Funding source: concern CUTGO will reduce other HHS OIG capacity
Relative to its intended legislative type, this bill is a concise administrative reorganization that integrates with the existing Inspector General statutory framework by amending 5 U.S.C. §401 and directing presidential appointments within a fixed timeframe while specifying funding must come from existing HHS OIG appropriations.
The bill requires the President to appoint separate Inspectors General (IGs) for the National Institutes of Health, the Centers for Disease Control and Prevention, and the Food and Drug Administration within one year.
It amends Title 5 definitions to include those agencies and specifies that implementation uses existing Office of Inspector General funds at HHS, with no new appropriations authorized.
Technically narrow and low‑cost, but politically sensitive oversight of health agencies and confirmation hurdles reduce chances.
Relative to its intended legislative type, this bill is a concise administrative reorganization that integrates with the existing Inspector General statutory framework by amending 5 U.S.C. §401 and directing presidential appointments within a fixed timeframe while specifying funding must come from existing HHS OIG appropriations.
Funding source: concern CUTGO will reduce other HHS OIG capacity
These are examples from the analysis, not a ranked list of the most-affected groups.
Funding source: concern CUTGO will reduce other HHS OIG capacity
Generally supportive because independent IGs can strengthen accountability, ethics, and clinical-trial oversight.
Concerned about adequacy of resources and potential politicization; some impacts are speculative because the bill does not detail powers or funding levels.
Cautiously favorable: targeted oversight can improve efficiency and accountability.
Worries center on duplication of functions, resource shifts, and avoiding partisan misuse.
Wants clear scopes and confirmation scrutiny.
Generally supportive because separate IGs increase scrutiny of federal health agencies often criticized by conservatives.
Approves CUTGO usage but desires aggressive investigations into regulatory overreach.
Some caution about potential partisan appointments.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow and low‑cost, but politically sensitive oversight of health agencies and confirmation hurdles reduce chances.
The bill has not accumulated any surfaced votes yet.
Funding source: concern CUTGO will reduce other HHS OIG capacity
Technically narrow and low‑cost, but politically sensitive oversight of health agencies and confirmation hurdles reduce chances.
Relative to its intended legislative type, this bill is a concise administrative reorganization that integrates with the existing Inspector General statutory framework by amending 5 U.S.C. §401 and directing presidentia…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.